The stock of Myovant Sciences Ltd. (NYSE:MYOV) is a huge mover today! The stock decreased 6.98% or $1.3 during the last trading session, reaching $17.32. About 3.75M shares traded or 66.64% up from the average. Myovant Sciences Ltd. (NYSE:MYOV) has declined 63.47% since December 4, 2018 and is downtrending. It has underperformed by 63.47% the S&P500.
The move comes after 7 months negative chart setup for the $1.55 billion company. It was reported on Dec, 4 by We have $16.11 PT which if reached, will make NYSE:MYOV worth $108.64 million less.

Analysts await Myovant Sciences Ltd. (NYSE:MYOV) to report earnings on February, 6. They expect $-0.79 EPS, up 24.04 % or $0.25 from last year’s $-1.04 per share. After $-0.79 actual EPS reported by Myovant Sciences Ltd. for the previous quarter, Wall Street now forecasts 0.00 % EPS growth.

Myovant Sciences Ltd. (NYSE:MYOV) Ratings Coverage

Among 2 analysts covering Myovant Sciences (NYSE:MYOV), 2 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Myovant Sciences has $2600 highest and $2000 lowest target. $23’s average target is 32.79% above currents $17.32 stock price. Myovant Sciences had 3 analyst reports since August 19, 2019 according to SRatingsIntel.

More notable recent Myovant Sciences Ltd. (NYSE:MYOV) news were published by: which released: “33 Stocks Moving In Wednesday’s Mid-Day Session – Benzinga” on November 27, 2019, also with their article: “Is Dynex Capital (DX) a Great Value Stock Right Now? – Nasdaq” published on November 22, 2019, published: “Retail Earnings Drag Stocks Into the Red – Schaeffers Research” on November 19, 2019. More interesting news about Myovant Sciences Ltd. (NYSE:MYOV) were released by: and their article: “Here’s What Hedge Funds Think About Myovant Sciences Ltd. (MYOV) – Yahoo Finance” published on May 02, 2019 as well as‘s news article titled: “CRISPR Therapeutics among healthcare gainers; Plus Therapeutics leads the losers – Seeking Alpha” with publication date: November 19, 2019.

Myovant Sciences Ltd., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for women's health and endocrine diseases. The company has market cap of $1.55 billion. The company's lead product is relugolix, an oral, once-daily, small molecule that acts as a gonadotropin-releasing hormone receptor antagonist, for the treatment of heavy menstrual bleeding related with uterine fibroids, endometriosis-associated pain, and advanced prostate cancer. It currently has negative earnings. It is also developing MVT-602, an oligopeptide kisspeptin agonist, for the treatment of female infertility as part of the hormonal preparation used in assisted reproduction.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Source link